Competition And Antitrust Laws Sweeping Asia Create New Hurdles For MNCs
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - The emergence and evolution of competition and antitrust regimes across Asia could create new hurdles for multinational pharmaceutical companies that control large swaths of a particular market or are looking to expand through mergers and acquisitions
You may also be interested in...
Hong Kong Pharmaceutical Industry Association Executive Director Sabrina Chan On Competition and R&D in Hong Kong: An Interview with PharmAsia News (Part 2 of 2)
Hong Kong, with a population of just under 7 million and long known for its status as one of the most open markets in the world, can be a challenging market for pharma companies because roughly half of the drugs sold in the Special Administrative Region of China go through its Hospital Authority. It can take up to three years to get an approved product on its list of available products. The Hong Kong Association of the Pharmaceutical Industry, which represents 42 companies including multinational companies that operate in Hong Kong, is fighting to cut through the red tape and get innovative drugs to patients faster while trying to stay on top of a stubborn counterfeit problem, Executive Director Sabrina Chan told PharmAsia News' Hong Kong bureau in an exclusive interview.
Insider Analysis From Sidley Austin LLP: Market Definition In Life Sciences Sector Under The Chinese Anti-Monopoly Law
By Chen Yang and Adrian Emch, Sidley Austin LLP, Beijin
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).